Between January and June 2018, Russia imported 5.9 bln RUB worth of pharmaceutical drugs produced in the EEU countries (wholesale prices, VAT included), which is in monetary terms more than 11% higher than that of the same period of 2017. In physical terms, Russia imported 99.7 mln units of drugs, which is 4.3% lower than that of the same period of 2017.

The import follows the current market tendencies: if calculated in minimum dosage units (MDU), the dynamics are +5%.

There has also been a change in the import line. Since January, Russia has imported 112 trademarks, including 12 new ones. In particular, the import of Ciprofloxacine (Kelun-Kazpharm) has risen by 191 times in monetary terms. Among the top 20 trademarks with the highest import in monetary terms are three products that were not imported in 2017. These are Docetaxel (Kelun-Kazpharm), Next Uno Express (Pharmstandard), and Cefepime (Farmgid.)

The absolute leader is still Belarus (+70%.) Pharmland and Pharmsynthez have the best dynamics, with a 25 and 9 times increase in monetary terms, respectively. Pharmsynthez imports only one product, which is anti-tumor drug Fludarabel. Kazakhstan follows with +29% , Kelun-Kazpharm has increased its import by nearly 8 times. Nobel-Ilac has the lowest dynamics, with -83%.

Volume and dynamics of pharmaceutical drug import from EEU countries to Russia (wholesale prices, VAT included) (2016 – June 2018)